Unveiling the Hidden Risk: Ticagrelor-Induced Bradyarrhythmias and Conduction Complications in ACS Patients—Case Series
Aleksandra Gorzynska-Schulz, Damian Stencelewski, Ludmiła Daniłowicz-Szymanowicz, Monika Lica-Gorzynska, Agata Firkowska, Elżbieta Wabich · 2025
Read Unveiling the Hidden Risk: Ticagrelor-Induced Bradyarrhythmias and Conduction Complications in ACS Patients—Case Series by Aleksandra Gorzynska-Schulz, Damian Stencelewski, Ludmiła Daniłowicz-Szymanowicz, Monika Lica-Gorzynska, Agata Firkowska, Elżbieta Wabich (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12842278.txt.
Description
Aleksandra Gorzynska-Schulz and co-authors published a case series in 2025 on a heart drug that slowed or stalled the heartbeat of two patients after heart attacks. The drug blocks platelets and is standard after such events, but it can raise levels of a chemical that slows the heart's wiring. Both patients were sixty-seven years old.
One woman suffered a full heart block with a forty-five-second pause and fainted. One man had repeated sinus pauses of up to five seconds. In both, stopping the drug and giving a countering medicine ended the problem, with no return seen. The team warns doctors to watch rhythm closely when the drug starts.
Catalog record
| CREATOR | Aleksandra Gorzynska-Schulz, Damian Stencelewski, Ludmiła Daniłowicz-Szymanowicz, Monika Lica-Gorzynska, Agata Firkowska, Elżbieta Wabich |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |